The North America induced pluripotent stem cells (iPSCs) market is entering a phase of rapid growth, underpinned by strong biotechnology infrastructure, advanced healthcare expenditure, and increasing adoption of regenerative and personalized medicine. The market is projected to be valued at US$714.3 million in 2025 and is expected to reach US$1,226.7 million by 2032, expanding at a compound annual growth rate (CAGR) of 8.0% during the forecast period from 2025 to 2032.
This acceleration follows a period of steady historical growth, where the market expanded at a CAGR of 6.8% between 2019 and 2024. The U.S., home to a highly advanced pharmaceutical and biotechnology ecosystem, is expected to continue leading the region, fueled by strong clinical trial activity, federal investment, and robust private-sector innovation.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35635
Key Market Drivers
Shift Toward Human-Relevant Preclinical Testing
A fundamental driver of iPSC adoption in North America is the regulatory and scientific shift toward more human-relevant preclinical testing models. The U.S. Food and Drug Administration (FDA) and Environmental Protection Agency (EPA) are both encouraging alternatives to traditional animal testing. The EPA’s stated plan to eliminate animal testing by 2035 is a pivotal milestone, reinforcing demand for scalable iPSC-based models.
iPSCs offer unparalleled advantages in toxicology, pharmacokinetics (ADME studies), and disease modeling. Differentiated iPSC-derived cell types such as cardiomyocytes, hepatocytes, and neurons replicate human physiology and genetic variations with high fidelity. This allows pharmaceutical companies to detect potential safety risks earlier in the drug development process, thereby reducing costly late-stage failures.
Demand for Personalized Medicine and Regenerative Therapies
The rising emphasis on personalized medicine is a key contributor to iPSC market growth in the U.S. and Canada. Patient-derived iPSCs are increasingly used for disease modeling and identifying treatment pathways tailored to individual genetic profiles. Simultaneously, regenerative medicine applications, particularly in oncology, cardiovascular, and neurological disorders, are gaining traction. Off-the-shelf iPSC-derived allogeneic therapies offer scalability and cost benefits, making them attractive for broader patient populations.
Expanding Academic-Industry Collaborations and CRO Integration
North America benefits from a strong academic ecosystem, with leading research institutions partnering with biotech and pharmaceutical companies to translate basic science into clinical innovation. The U.S. National Institutes of Health (NIH), distributing over US$31 billion annually, plays a pivotal role in funding iPSC-based projects.
At the same time, contract research organizations (CROs) are scaling their capabilities in iPSC-based drug screening, cell line development, and disease modeling. This outsourcing trend enables pharmaceutical companies to accelerate research and lower infrastructure costs, contributing to commercialization momentum in the region.
Market Barriers
Despite strong drivers, the high cost of iPSC products remains a significant barrier to adoption, particularly among smaller institutions. Creating a research-grade iPSC line can cost between US$10,000 and US$25,000, with timelines extending six to nine months. Clinical-grade lines are even more expensive. In the U.S., academic core facilities may charge more than US$4,800 for a few iPSC lines, excluding additional testing and expansion costs.
These expenses limit participation for early-stage biotech firms and smaller universities, curbing exploratory research and slowing broader uptake. Without cost reduction strategies, smaller players may remain dependent on ready-to-use cell lines and commercial assay kits, creating market entry barriers.
Category-Wise Analysis
Product Type Insights
Reagents and kits are the largest product category in the North America iPSC market, reflecting their indispensable role in stem cell reprogramming, differentiation, and expansion. The growing reliance on standardized, ready-to-use kits reduces variability in workflows and ensures reproducibility in both academic and commercial labs.
Consumables and kits are also the fastest-growing product segment, supported by increasing adoption of iPSC platforms for drug discovery and toxicity testing. Rising NIH funding and the expansion of CRO services are expected to maintain this momentum through 2032.
Cell Type Insights
Allogeneic iPSCs dominate the North American market due to their scalability and suitability for standardized therapeutic applications. Unlike autologous cells, which are patient-specific and resource-intensive, allogeneic iPSCs can be produced in bulk, stored, and distributed as off-the-shelf therapies. This makes them more practical for high-demand applications in regenerative medicine and oncology.
The strong research infrastructure in the U.S. and Canada, coupled with investments in developing iPSC-derived allogeneic cell banks, reinforces the dominance of this segment.
Application Insights
Drug development represents the fastest-growing application area, fueled by the pharmaceutical industry’s demand for improved preclinical testing and reduced attrition rates in late-stage trials. iPSCs enable disease-specific modeling, high-throughput screening, and patient stratification strategies, significantly enhancing drug discovery efficiency.
These applications align closely with industry priorities, making drug development the most rapidly expanding segment within the iPSC landscape.
Country-Level Insights
United States
The U.S. is the undisputed leader in the North America iPSC market, supported by advanced biotechnology infrastructure, robust healthcare expenditure, and strong government backing. With the rise of iPSC-based “micromedicine” approaches, researchers can model diseases at an individual level, while “macromedicine” applications enable high-throughput analyses across patient populations.
Emerging applications include biomarker discovery for patient stratification, allowing pharmaceutical companies to select trial participants most likely to benefit from therapies. This reduces trial costs and enhances success rates.
Canada
Canada is also witnessing increased investment in iPSC research, particularly in regenerative medicine and oncology. Federal funding programs and collaborations with U.S. institutions are driving cross-border research initiatives. While smaller in scale compared to the U.S., Canada’s contributions add resilience to the regional market.
Competitive Landscape
The North American iPSC market is competitive, with major players leveraging innovation, partnerships, and acquisitions to strengthen their positions. Key industry participants include FUJIFILM Cellular Dynamics, Thermo Fisher Scientific Inc., Lonza, Sartorius AG, Merck KGaA, Miltenyi Biotec, Hitachi Ltd., Takara Bio Inc., Terumo Corporation, Horizon Discovery Group plc, and Cell Applications, Inc.
These companies are focusing on expanding product portfolios, launching clinical-grade iPSCs, and investing in scalable differentiation platforms. Strategic collaborations with academic institutions and CROs are common, enabling faster commercialization of novel therapies.
Recent Industry Developments
April 2025 – Thermo Fisher Scientific launched its Advanced Therapies Collaboration Center in Greater San Diego, designed to accelerate the development of next-generation cell therapies.
April 2025 – Hitachi, in collaboration with Kyoto University’s CiRA Foundation, announced a demonstration project for automated culture systems to lower the cost of iPSC-based therapies.
September 2024 – FUJIFILM Cellular Dynamics introduced its iCell® Sensory Neurons, supporting neuroscience research and novel pain drug discovery globally.
These developments underscore the market’s focus on scalability, cost reduction, and expansion into new therapeutic domains.
Investment Landscape
The U.S. government has committed billions of dollars through the NIH and other agencies to advance stem cell research, including iPSCs. This funding not only supports regenerative medicine and personalized therapy initiatives but also drives innovation in preclinical testing and disease modeling.
Private-sector investment remains equally strong, with venture capital flowing into biotech startups and partnerships focused on iPSC commercialization. Academic-industry collaborations are also generating new business opportunities, reinforcing North America’s position as a global leader in iPSC innovation.
Outlook and Future Opportunities
The North America induced pluripotent stem cells market is poised for transformative growth over the next decade. Advances in automation, cost reduction, and scalable manufacturing are expected to overcome current barriers, opening pathways for broader adoption.
The convergence of iPSCs with emerging technologies such as artificial intelligence (AI) and organ-on-chip systems will further enhance predictive modeling and accelerate the drug discovery process. Moreover, the growing emphasis on eliminating animal testing creates a regulatory environment highly favorable to iPSC-based platforms.
By 2032, North America is projected to cement its role as the global hub for iPSC research, commercialization, and therapeutic development. The region’s combination of funding, infrastructure, and innovation capacity positions it for long-term leadership in regenerative medicine and personalized healthcare solutions.
Read Related Reports:
